NCT07023731View on ClinicalTrials.gov

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

April 2, 2029

Conditions
KRAS G12D MutationAdvanced Solid Cancer
Interventions
DRUG

ARV-806

Intravenous infusion at assigned dose and dosing schedule

Trial Locations (4)

22031

RECRUITING

Clinical Trial Site, Fairfax

28078

RECRUITING

Clinical Trial Site, Huntersville

49546

RECRUITING

Clinical Trial Site, Grand Rapids

78229

RECRUITING

Clinical Trial Site, San Antonio

Sponsors

Lead Sponsor

Arvinas Inc.
All Listed Sponsors
lead

Arvinas Inc.

INDUSTRY

NCT07023731 - A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Biotech Hunter | Biotech Hunter